PRESS-RELEASE ·Filed Apr 16, 2026

ZYME

Zymeworks Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight • Neutral

Traders should monitor the May 7 earnings call for updates on cash runway, pipeline progress, and any changes to revenue or expense outlook, especially given the significant prior-quarter miss.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ZYME ▼ -8.31% at T+60d
NEUTRAL call ✗ call lost -8.31% · α vs SPY -15.36% · entry $27.20 → $24.94
Entry anchored
Apr 16, 05:53 AM ET
via exchange tick
T+1d
+2.21%
call +2.21% · α +0.99%
$27.80
settled 6mo ago
T+5d
+0.85%
call +0.85% · α -0.14%
$27.43
settled 5mo ago
T+20d
-9.67%
call -9.67% · α -15.48%
$24.57
settled 5mo ago
T+60d
-8.31%
call -8.31% · α -15.36%
$24.94
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Zymeworks announced it will report Q1 2026 financial results on May 7, 2026, with no actual financials disclosed in this press release. The company missed consensus EPS by 444% in the prior quarter (Q4 2025), signaling ongoing profitability challenges. This notice is routine and provides no update on performance or guidance.

Key Financial Metrics

EPS
$-0.55
est $-0.10 · -444.7%
Revenue
$34.9M
est $34.9M · 0.0%
Rating
strong miss

Key Facts

  • Company to report Q1 2026 financial results on May 7, 2026, after market close
  • Conference call scheduled for 4:30 pm ET to discuss results and provide corporate update
  • No financial data released in this announcement
  • Q4 2025 EPS was $-0.55 vs. consensus of $-0.10, a 444.7% miss
  • Q4 2025 revenue was $34.9M, in line with analyst estimates

Financial Impact

No immediate financial impact from this filing; material impact expected on May 7 with full results

epsrevenueguidance

Risk Factors

  • Continued negative EPS and high R&D spend could pressure cash reserves
  • Lack of near-term commercial revenue increases reliance on partnerships and financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3275119
12 reports for ZYME
Performance horizon
88% Hit rate 7 of 8 directional calls best @ T+60▲ +16.72%Jun 14, 2026
Filters
Rows
Reports for ZYME — sortable, filterable
TypeNow
Aug 25, 2026
5w ago
8-K
BULLISH ★ 8/10
$27.47 $27.50▲ +0.11%▼ −0.87%$25.18 (−8.32%)
Jul 16, 2026
11w ago
Press Release
BEARISH ★ 6/10
$24.19 $25.76▼ −6.49%▼ −2.87%$25.18 (−4.11%)
Jun 29, 2026
13w ago
Press Release
BULLISH ★ 7/10
$24.10 $22.86▼ −5.15%▼ −4.87%$25.18 (+4.50%)
Jun 14, 2026
15w ago
Press Release
BULLISH ★ 6/10
$23.26 $24.94▲ +7.22%▲ +7.97%$25.18 (+8.28%)
May 15, 2026
19w ago
3
NEUTRAL ★ 2/10
$24.43 $22.49▼ −7.94%▼ −9.52%$25.18 (+3.09%)
Apr 21, 2026
23w ago
Press Release
BULLISH ★ 8/10
$28.53 $24.40▼ −14.48%▼ −17.64%$25.18 (−11.72%)
Apr 17, 2026
23w ago
Press Release
BULLISH ★ 7/10
$27.80 $23.96▼ −13.81%▼ −19.18%$25.18 (−9.41%)
Apr 16, 2026
24w ago
Press Release
NEUTRAL ★ 3/10
$27.20 $24.57▼ −9.67%▼ −15.48%$25.18 (−7.41%)
Apr 10, 2026
24w ago
3
NEUTRAL ★ 3/10
$26.17 $24.03▼ −8.18%▼ −15.91%$25.18 (−3.76%)
Mar 17, 2026
28w ago
Press Release
NEUTRAL ★ 3/10
$23.45 $27.20▲ +15.99%▲ +9.94%$25.18 (+7.40%)
Showing 10 of 12

US Market Status

Market Open — Closes in 1h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 16, 2026